FDA approves first DNA-based treatment for a rare airway disease
Published
The FDA gave accelerated approval to Inovio's Voceryq for adults with recurrent respiratory papillomatosis, an HPV-caused condition that grows wart-like tumors in the airway and often requires repeated surgery. In its study, about a quarter of patients needed no surgery for a year. The company must still run a confirming trial.
Source: FDA
This is a plain-language summary. Read the original source for full details.